4565 Sosei Group Corporation

Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum

Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum

TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The meeting will be held in person in Tokyo for institutional investors, securities analysts and the press and will also be available via a live webcast. Please click  to register for the event.

  • Date: Thursday, 13 October 2022 
  • Time: 3:30 pm – 5:30 pm JST (7:30 am – 9:30 am BST) 
  • Presenters:
Chris Cargill, President and CEO
 Corporate presentation, vision, strategy and progress 
  
 Matt Barnes, Head of UK R&D
 Focusing on out-licensed and partnered programs 
  
 Rie Suzuki, Senior Director, Translational Biology
 Focused on wholly owned, in-house programs

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit

LinkedIn: | Twitter: | YouTube:

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, Chief Financial Officer

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Candelle Chong, SVP Investor Relations and Corporate Strategy

Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 |

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, Frazer Hall, Eleanor Perkin

+44 (0)203 928 6900 |



EN
27/09/2022

Underlying

4565Sosei Group Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sosei Group Corporation

 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lill...

Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a definitive agre...

March 31, 2026 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa P...

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration w...

March 5, 2026 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Submits Marketing Authorization Application for Daridorex...

Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO) Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; ...

March 4, 2026 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Proposes Changes to its Board of Directors

Nxera Pharma Proposes Changes to its Board of Directors Mr. Takeo Morooka nominated for appointment as new External DirectorMs. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Committee. The appointments are expected to be ratified officially, subject to the passing of re...

February 13, 2026 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Operational Highlights and Consolidated Results for the F...

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025 Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed . Christopher Cargill, President and CEO of Nxera Pharma, commented: “2025 was a year of disciplined execution and strategic progress for Nxera, as we continued to build a more focused, resilient and scalable ...

February 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch